Fundz
Back to SEC Filings
10-KMEDIUM RiskDETERIORATING

ENZON PHARMACEUTICALS, INC.

www.viskase.com
Filed: Mar 2, 2026 CIK: 0000727510Manufacturing
View original filing on SEC.gov

AI Executive Summary

AI-powered analysis of 10-K filing content

Enzon Pharmaceuticals has transformed from an active pharmaceutical company into a shell company operating as a public acquisition vehicle with no clinical operations for over ten years. The company has lost its key Vicineum licensing agreement and appears to be in a state of corporate limbo with minimal business activity.

Red Flags Detected (6)

No clinical operations for more than ten years

Limited corporate operations with minimal business activity

Loss of Vicineum marketing agreement - licensee was canceled by counterparty

3 more red flags detected

Key Takeaways

Enzon is no longer a functioning pharmaceutical company

The company exists primarily as a public shell seeking acquisition opportunities

3 more takeaways

Filing Overview

Form TypeAnnual Report (10-K)
Filing DateMar 2, 2026
Risk LevelMEDIUM
TrendDETERIORATING
AI Confidence85%
Red Flags6

What This Means

Deteriorating Trend: Conditions are worsening compared to previous filings. This may create opportunities for service providers.

Annual Report: Comprehensive filing covering the full fiscal year with audited financial statements.

View Full Filing on SEC.govBrowse More Filings